[144] Nektar Therapeutics SEC Filing
Nektar Therapeutics (NKTR) notice reports a proposed sale of 6,666 common shares with an aggregate market value of $256,837.92, representing a portion of ~19.02 million shares outstanding. The filing identifies the broker as Fidelity Brokerage Services LLC and lists the approximate date of sale as 09/05/2025 on NASDAQ. The 6,666 shares to be sold were acquired through restricted stock vesting between 05/15/2017 and 05/15/2021 as compensation from the issuer, and the acquisition table shows the same 6,666-share total when summed. The filer also disclosed three sales in the prior three months totaling 8,239 shares for gross proceeds of $261,188.89. The notice includes the seller's attestation regarding absence of undisclosed material adverse information.
Nektar Therapeutics (NKTR) ha comunicato la proposta di vendita di 6.666 azioni ordinarie per un valore di mercato complessivo di $256.837,92, rappresentanti una parte di circa 19,02 milioni di azioni in circolazione. La segnalazione indica il broker come Fidelity Brokerage Services LLC e riporta la data approssimativa della vendita al 05/09/2025 sul NASDAQ. Le 6.666 azioni da vendere sono state acquisite tramite il vesting di azioni vincolate tra il 15/05/2017 e il 15/05/2021 come compenso dall'emittente; la tabella delle acquisizioni mostra lo stesso totale di 6.666 azioni. Il dichiarante ha inoltre reso noto tre vendite nei tre mesi precedenti per un totale di 8.239 azioni e proventi lordi pari a $261.188,89. La notifica include anche l'attestazione del venditore sull'assenza di informazioni materiali avverse non divulgate.
Nektar Therapeutics (NKTR) notific贸 una propuesta de venta de 6.666 acciones ordinarias por un valor de mercado agregado de $256.837,92, que representa una porci贸n de alrededor de 19,02 millones de acciones en circulaci贸n. El aviso identifica al corredor como Fidelity Brokerage Services LLC y se帽ala la fecha aproximada de la venta el 05/09/2025 en el NASDAQ. Las 6.666 acciones a vender se adquirieron mediante la consolidaci贸n de acciones restringidas entre el 15/05/2017 y el 15/05/2021 como remuneraci贸n del emisor; la tabla de adquisici贸n muestra el mismo total de 6.666 acciones. El declarante tambi茅n divulg贸 tres ventas en los tres meses anteriores por un total de 8.239 acciones y unos ingresos brutos de $261.188,89. La notificaci贸n incluye la declaraci贸n del vendedor sobre la ausencia de informaci贸n adversa material no divulgada.
Nektar Therapeutics (NKTR)電� 齑� 鞁滌灔臧�旃� $256,837.92鞐� 頃措嫻頃橂姅 6,666 氤错喌欤� 毵り皝 鞝滌晥鞚� 瓿奠嫓頄堨溂氅�, 鞚措姅 鞎� 1,902毵� 欤检潣 鞚茧秬鞐� 頃措嫻頃╇媹雼�. 鞝滌稖靹滊電� 欷戧皽鞚胳潉 Fidelity Brokerage Services LLC搿� 氇呾嫓頃橁碃, 毵り皝 鞓堨爼鞚检潉 2025-09-05瓴届溂搿� 旮办灛頄堨溂氅� 瓯半灅靻岆姅 NASDAQ鞛呺媹雼�. 毵る弰 鞓堨爼鞚� 6,666欤茧姅 氚滍枆靷攵赌韯� 氤挫垬搿滌劀 2017-05-15攵赌韯� 2021-05-15 靷澊鞐� 鞝滍暅欤检嫕 氩犾姢韺呾潉 韱淀暣 旆摑霅� 瓴冹澊瓿�, 旆摑 響滌棎電� 頃╆硠 6,666欤缄皜 霃欖澕頃橁矊 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃鞛愲姅 霕愴暅 斓滉芳 3臧滌洈 雮挫棎 齑� 8,239欤茧ゼ 毵る弰頃橃棳 齑濎垬鞛� $261,188.89毳� 鞏混棃雼り碃 瓿店皽頄堨姷雼堧嫟. 瓿奠嫓電� 霕愴暅 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗠嫟電� 韺愲Г鞛愳潣 歆勳垹鞚� 韽暔頃╇媹雼�.
Nektar Therapeutics (NKTR) a notifi茅 une proposition de vente de 6 666 actions ordinaires pour une valeur marchande totale de 256 837,92 $, repr茅sentant une partie d'environ 19,02 millions d'actions en circulation. Le d茅p么t identifie le courtier comme Fidelity Brokerage Services LLC et indique une date approximative de vente au 05/09/2025 sur le NASDAQ. Les 6 666 actions 脿 vendre ont 茅t茅 acquises par vesting d'actions restreintes entre le 15/05/2017 et le 15/05/2021 en tant que r茅mun茅ration de l'茅metteur ; le tableau d'acquisition affiche le m锚me total de 6 666 actions. Le d茅clarant a 茅galement divulgu茅 trois ventes au cours des trois mois pr茅c茅dents totalisant 8 239 actions pour des produits bruts de 261 188,89 $. L'avis inclut l'attestation du vendeur concernant l'absence d'informations d茅favorables mat茅rielles non divulgu茅es.
Nektar Therapeutics (NKTR) meldet einen vorgeschlagenen Verkauf von 6.666 Stammaktien mit einem Gesamtmarktwert von $256.837,92, was einen Teil von etwa 19,02 Millionen ausstehenden Aktien darstellt. Das Formular nennt den Broker als Fidelity Brokerage Services LLC und f眉hrt das ungef盲hre Verkaufsdatum als 05.09.2025 an der NASDAQ auf. Die zu verkaufenden 6.666 Aktien wurden als Verg眉tung durch Restricted-Stock-Vesting zwischen dem 15.05.2017 und dem 15.05.2021 erworben; die Erwerbstabelle weist dieselbe Gesamtzahl von 6.666 Aktien aus. Der Melder gab zudem drei Verk盲ufe in den vorangegangenen drei Monaten mit insgesamt 8.239 Aktien und Bruttoerl枚sen von $261.188,89 an. Die Mitteilung enth盲lt au脽erdem die Zusicherung des Verk盲ufers, dass keine nicht offengelegten, wesentlichen negativen Informationen vorliegen.
- None.
- None.
Insights
TL;DR: Officer/insider plans a small, routine sale of vested shares; disclosed recent sales show ongoing liquidity events.
The filing documents a proposed Rule 144 sale of 6,666 vested common shares via Fidelity with an estimated market value of $256,838 against ~19.02 million shares outstanding, a de minimis fraction of float. The acquisition history shows these shares arose from periodic restricted stock vesting from 2017鈥�2021, indicating compensation-origin shares rather than new issuance. Recent sales in the prior three months (8,239 shares, $261,188.89) suggest the filer has been orderly disposing of vested stock. From a securities-structure perspective, this is a routine insider liquidity disclosure and does not, by itself, indicate corporate operational change.
TL;DR: Filing is a standard Rule 144 notice with required representations; no governance red flags disclosed.
The notice includes required attestations and lists a broker and planned sale date, complying with Rule 144 formality. The shares were received as compensation via restricted stock vesting over multiple years, which is typical for executives or employees. The filer affirmed no undisclosed material adverse information, and the filing shows transparent aggregation of prior sales in the three-month lookback. There are no indications in this document of unusual trading plans, 10b5-1 reliance dates, or compensatory irregularities; therefore governance impact is neutral based solely on the disclosed facts.
Nektar Therapeutics (NKTR) ha comunicato la proposta di vendita di 6.666 azioni ordinarie per un valore di mercato complessivo di $256.837,92, rappresentanti una parte di circa 19,02 milioni di azioni in circolazione. La segnalazione indica il broker come Fidelity Brokerage Services LLC e riporta la data approssimativa della vendita al 05/09/2025 sul NASDAQ. Le 6.666 azioni da vendere sono state acquisite tramite il vesting di azioni vincolate tra il 15/05/2017 e il 15/05/2021 come compenso dall'emittente; la tabella delle acquisizioni mostra lo stesso totale di 6.666 azioni. Il dichiarante ha inoltre reso noto tre vendite nei tre mesi precedenti per un totale di 8.239 azioni e proventi lordi pari a $261.188,89. La notifica include anche l'attestazione del venditore sull'assenza di informazioni materiali avverse non divulgate.
Nektar Therapeutics (NKTR) notific贸 una propuesta de venta de 6.666 acciones ordinarias por un valor de mercado agregado de $256.837,92, que representa una porci贸n de alrededor de 19,02 millones de acciones en circulaci贸n. El aviso identifica al corredor como Fidelity Brokerage Services LLC y se帽ala la fecha aproximada de la venta el 05/09/2025 en el NASDAQ. Las 6.666 acciones a vender se adquirieron mediante la consolidaci贸n de acciones restringidas entre el 15/05/2017 y el 15/05/2021 como remuneraci贸n del emisor; la tabla de adquisici贸n muestra el mismo total de 6.666 acciones. El declarante tambi茅n divulg贸 tres ventas en los tres meses anteriores por un total de 8.239 acciones y unos ingresos brutos de $261.188,89. La notificaci贸n incluye la declaraci贸n del vendedor sobre la ausencia de informaci贸n adversa material no divulgada.
Nektar Therapeutics (NKTR)電� 齑� 鞁滌灔臧�旃� $256,837.92鞐� 頃措嫻頃橂姅 6,666 氤错喌欤� 毵り皝 鞝滌晥鞚� 瓿奠嫓頄堨溂氅�, 鞚措姅 鞎� 1,902毵� 欤检潣 鞚茧秬鞐� 頃措嫻頃╇媹雼�. 鞝滌稖靹滊電� 欷戧皽鞚胳潉 Fidelity Brokerage Services LLC搿� 氇呾嫓頃橁碃, 毵り皝 鞓堨爼鞚检潉 2025-09-05瓴届溂搿� 旮办灛頄堨溂氅� 瓯半灅靻岆姅 NASDAQ鞛呺媹雼�. 毵る弰 鞓堨爼鞚� 6,666欤茧姅 氚滍枆靷攵赌韯� 氤挫垬搿滌劀 2017-05-15攵赌韯� 2021-05-15 靷澊鞐� 鞝滍暅欤检嫕 氩犾姢韺呾潉 韱淀暣 旆摑霅� 瓴冹澊瓿�, 旆摑 響滌棎電� 頃╆硠 6,666欤缄皜 霃欖澕頃橁矊 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃鞛愲姅 霕愴暅 斓滉芳 3臧滌洈 雮挫棎 齑� 8,239欤茧ゼ 毵る弰頃橃棳 齑濎垬鞛� $261,188.89毳� 鞏混棃雼り碃 瓿店皽頄堨姷雼堧嫟. 瓿奠嫓電� 霕愴暅 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗠嫟電� 韺愲Г鞛愳潣 歆勳垹鞚� 韽暔頃╇媹雼�.
Nektar Therapeutics (NKTR) a notifi茅 une proposition de vente de 6 666 actions ordinaires pour une valeur marchande totale de 256 837,92 $, repr茅sentant une partie d'environ 19,02 millions d'actions en circulation. Le d茅p么t identifie le courtier comme Fidelity Brokerage Services LLC et indique une date approximative de vente au 05/09/2025 sur le NASDAQ. Les 6 666 actions 脿 vendre ont 茅t茅 acquises par vesting d'actions restreintes entre le 15/05/2017 et le 15/05/2021 en tant que r茅mun茅ration de l'茅metteur ; le tableau d'acquisition affiche le m锚me total de 6 666 actions. Le d茅clarant a 茅galement divulgu茅 trois ventes au cours des trois mois pr茅c茅dents totalisant 8 239 actions pour des produits bruts de 261 188,89 $. L'avis inclut l'attestation du vendeur concernant l'absence d'informations d茅favorables mat茅rielles non divulgu茅es.
Nektar Therapeutics (NKTR) meldet einen vorgeschlagenen Verkauf von 6.666 Stammaktien mit einem Gesamtmarktwert von $256.837,92, was einen Teil von etwa 19,02 Millionen ausstehenden Aktien darstellt. Das Formular nennt den Broker als Fidelity Brokerage Services LLC und f眉hrt das ungef盲hre Verkaufsdatum als 05.09.2025 an der NASDAQ auf. Die zu verkaufenden 6.666 Aktien wurden als Verg眉tung durch Restricted-Stock-Vesting zwischen dem 15.05.2017 und dem 15.05.2021 erworben; die Erwerbstabelle weist dieselbe Gesamtzahl von 6.666 Aktien aus. Der Melder gab zudem drei Verk盲ufe in den vorangegangenen drei Monaten mit insgesamt 8.239 Aktien und Bruttoerl枚sen von $261.188,89 an. Die Mitteilung enth盲lt au脽erdem die Zusicherung des Verk盲ufers, dass keine nicht offengelegten, wesentlichen negativen Informationen vorliegen.
